Tuesday, September 22, 2026
← Back to archivePolicy
Policy•KFF•Sep 22, 2026
AI: To Regulate, or Not to Regulate?
background ▾
- •Grogan contends that poorly designed AI regulation poses greater risk to healthcare innovation than inadequate regulation, contrasting with industry calls for government oversight
- •CMS reimbursement structures are identified as needing reform to accommodate AI-enabled healthcare solutions
Policy•STAT News•Sep 22, 2026
Opinion: Social media bans are passing around the world. How will we know if they help teens?
background ▾
- •Australia's social media ban for under-16s is proving difficult to implement, with early evaluation showing 80%+ continued platform access three months post-implementation, making it premature to assess mental health impact
Meta
→ Read original articlePolicy•KFF•Sep 21, 2026
What We Know from the Latest PEPFAR Data: Analysis of FY 2025 Quarter 4 Results
background ▾
- •Prevention services contracted significantly in FY 2025 Q4—PrEP and DREAMS program support were 'significantly scaled back'—raising concern for future HIV incidence increases despite 26 million lives previously saved by PEPFAR.
- •PEPFAR's historic data platform was removed in early 2025 and restored without FY 2025 program data; only Q4 snapshot released due to 'data reporting and implementation challenges,' limiting ability to assess full-year impact of administrative restructuring.
- •Future PEPFAR data transparency is uncertain as U.S. global health strategy shifts toward country-bilateral agreements rather than disease-specific programming, potentially affecting ongoing independent epidemiologic monitoring and payer/NGO access to program performance metrics.
antiretroviral therapy (ART)pre-exposure prophylaxis (PrEP)
→ Read original articlePolicy•KFF•Sep 21, 2026
Implementation of 2025 Reconciliation Law: Medicaid Managed Care Rate Setting Uncertainty & Potential Plan Exits
background ▾
- •Medicaid managed care profitability is under pressure with average medical loss ratios rising to 91% in 2024 (from 88% in 2023), the highest in the past decade, driven by higher member acuity and uncertain cost projections under new federal reconciliation law provisions
- •Large multi-state MCO operators including Elevance Health are announcing market exits (DC, Louisiana) due to rate-setting uncertainty and financial risk from inability to prospectively adjust capitation rates amid unpredictable enrollment and health cost impacts
- •States face unprecedented rate-setting challenges in 2025-2026 as they attempt to model impacts of work requirements, frequent eligibility redeterminations for expansion adults, provider tax caps, and directed payment reductions on member enrollment, acuity, and plan financial viability
Elevance Health
→ Read original articlePolicy•KFF•Sep 21, 2026
Overview of Health Coverage and Care for Individuals with Limited English Proficiency (LEP)
background ▾
- •28.5 million Americans (9% of population age 5+) have LEP as of 2024, up from 8% in 2021; this growing population experiences significant health insurance coverage gaps and poor health outcomes driven by language barriers
Market Access
Market Access•Fierce Biotech•Sep 21, 2026
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
background ▾
- •Novo is launching a 'Consumer Rx' segment to directly market prescription medications to consumers in high-demand disease areas (obesity, diabetes, hemophilia, women's/men's health), leveraging its established direct-to-consumer distribution capabilities built through GLP-1 success.
- •The company targets five blockbuster launches by 2030 generating >$23 billion in sales within a decade, anchored by near-term catalysts including CagriSema (diabetes/weight loss), denecimig (hemophilia), and zenagamtide (obesity), with explicit acknowledgment of development risk.
- •Investor sentiment remains cautious despite bold promises: 8% stock decline suggests market skepticism about pipeline execution risk, manufacturing scale-up feasibility, and lack of clarity on M&A strategy to strengthen competitive position against Eli Lilly and other obesity-space entrants.
Novo NordiskEli LillyCagriSemacagrilintidesemaglutide
→ Read original articleMarket Access•Fierce Biotech•Sep 22, 2026
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
background ▾
- •Iambic is advancing IAM1363, a potentially first-in-class oral HER2 TKI with DFG-out binding mode and multi-indication potential (breast, gastric, NSCLC), toward registrational trials in 2027
- •The company has secured $1.7B in biobucks from Takeda plus additional partnerships with AbbVie and other major pharma, validating its AI platform technology (NeuralPLexer)
- •Monitor IAM1363 Phase 1 data readouts and registrational trial initiation timeline; watch IPO pricing and allocation decisions as indicator of biotech market sentiment on AI-enabled drug discovery
Iambic TherapeuticsTakedaAbbVieIAM1363IAM217IAM-C1
→ Read original articleMarket Access•STAT News•Sep 22, 2026
Opinion: The science on relieving cancer symptoms is clear. Why isn’t insurance paying?
background ▾
- •Major medical societies (ASCO, NCCN, SIO) now endorse integrative oncology with evidence-based clinical guidelines, yet insurance coverage remains fragmented and geographically dependent, creating inequitable access.
- •Integrative therapies show clinical benefit in randomized trials for pain, fatigue, nausea, anxiety, and immune function, yet are often not reimbursed while expensive drugs with modest benefit routinely are covered—a potential economic inefficiency.
- •Watch for payer coverage policy changes, potential legislation mandating coverage alignment with major society guidelines, and whether ASCO/NCCN escalate advocacy efforts to address reimbursement barriers.
acupuncturemindfulness-based interventionsexercise and nutrition counseling
→ Read original articleMarket Access•Endpoints News•Sep 21, 2026
Iambic signs AbbVie deal, releases next generation of Enchant model
background ▾
- •AbbVie partnership validates Iambic's Enchant AI platform and signals pharma industry confidence in AI-enabled drug discovery
- •Next-generation Enchant model release demonstrates continued innovation in Iambic's core technology, though specific improvements and applications are not detailed
Iambic TherapeuticsAbbVie
→ Read original articleMarket Access•Endpoints News•Sep 21, 2026
Telix and radioisotope maker ITM merge in deal worth up to $2.35B
background ▾
- •Telix acquires ITM for $1.65B upfront plus up to $700M in milestones, creating a leading radiopharmaceutical company with integrated isotope manufacturing
- •Deal value contingent on resolving recent regulatory rejection, suggesting clinical or regulatory headwinds that could impact deal economics
- •Monitor regulatory outcomes on rejected program and integration execution; vertical integration in radioisotope supply is strategically significant given supply chain constraints in theranostics
Telix PharmaceuticalsITM Isotope Technologies Munich SE
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 22, 2026
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
background ▾
- •Enicepatide demonstrated 2.65% HbA1c reduction and 15.5% weight loss in phase 2, with 62% of patients achieving HbA1c ≤5.7%, appearing superior to retatrutide on these cross-trial metrics despite methodological limitations
- •The lack of weight loss plateau in 48-week data suggests potential for deeper efficacy in longer-duration trials, addressing a key differentiator versus established competitors
- •Roche's broad phase 3 program (obesity, glycemic control, cardiovascular outcomes starting H1 2025) will determine whether enicepatide can overcome analyst skepticism about Roche's competitive positioning against Lilly's entrenched portfolio
RocheEli LillyNovo NordiskenicepatideCT-388tirzepatide
→ Read original articleClinical Trials•Fierce Biotech•Sep 21, 2026
With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’
background ▾
- •First-in-class demonstration of an orexin agonist efficacy in ADHD (non-sleep indication), opening a potentially massive new therapeutic category and validating the broader neurobiological hypothesis for orexin pathway in arousal/attention disorders.
- •CEO explicitly positioning ALKS 7290 as a 'company changer' blockbuster given the scale of the ADHD market (especially in children, where diagnosis is rising) combined with Alkermes' pipeline of three orexin agonists across multiple indications.
- •Watch phase 2 trial readout (four-week, multi-dose design) and competitive moves by other biotech/pharma to develop orexin agonists for ADHD; pediatric trial initiation timelines; and regulatory pathway clarity for this nascent drug class outside narcolepsy.
AlkermesTakedaALKS 7290Orzeyfulalixorexton
→ Read original articleClinical Trials•Endpoints News•Sep 21, 2026
Novo offers low-dose CagriSema data as approval decision looms
background ▾
- •Novo disclosed CagriSema low-dose efficacy data demonstrating competitive positioning in the GLP-1 receptor agonist space, with regulatory approval decision expected imminently
- •The company's strategic data release at a capital markets event indicates confidence in the asset and potential near-term regulatory pathway clarity
- •Monitor for FDA/EMA approval decision timeline and commercial launch strategy, particularly positioning against established players (Novo's Ozempic/Wegovy, Eli Lilly's Mounjaro/Zepbound)
Novo NordiskCagriSema
→ Read original articleClinical Trials•Fierce Biotech•Sep 21, 2026
Beyond clinical endpoints: Rethinking ALS drug development through disease biology
background ▾
- •FDA's tofersen approval based on NfL biomarker data has established a precedent for biology-driven ALS trial design, shifting the field away from traditional clinical endpoints alone
- •Diagnostic delay (months between symptom onset and specialist consultation) rather than late ALS diagnosis itself is the primary impediment to trial enrollment and drug efficacy demonstration
- •Biomarker panels tracking neuronal injury, inflammation, and muscle health across ALS subtypes are becoming standard regulatory expectations, not optional scientific enhancements
Neurizon TherapeuticsBarrow Neurological InstituteSt. Joseph's Hospital and Medical Centertofersen
→ Read original articleClinical Trials•Endpoints News•Sep 21, 2026
Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial
background ▾
- •Cue Biopharma's chronic hives candidate achieved Phase 2 efficacy endpoints, validating the company's strategic shift from oncology to immunology
- •The program targets a market currently dominated by Xolair, creating potential commercial opportunity if differentiation is demonstrated
- •Investor attention will focus on Phase 3 trial design, competitive positioning vs. Xolair, and whether the data supports a differentiated mechanism or safety/efficacy profile
Cue BiopharmaRocheXolairomalizumab
→ Read original article